X-Message-Number: 31822
From: "Leo" <>
Subject: anti ischemia drug
Date: Wed, 22 Jul 2009 21:25:52 +0200

New anti-ischemia drug useble for cryo patients?.
maybe its useble before its aproved by the FDA.

http://www.cbiolabs.com/applications_04.php



Acute Organ Failure


CBLI's finding that Protectans are able to prevent death of normal cells in the 
face of stresses that normally induce apoptosis suggests a wide range of 
potential applications for these compounds. In addition to radiation exposure, 
another type of stress that leads to tissue damage through apoptosis of normal, 
non-cancerous cells is the ischemia (limited blood flow leading to local 
hypoxia) that occurs during acute medical conditions such as stroke, heart 
attack and renal failure.


CBLI researchers in collaboration with investigators from the Cleveland Clinic 
have demonstrated that injection of Protectan CBLB502, an optimized derivative 
of bacterial flagellin, effectively prevents acute renal failure and subsequent 
death in a mouse model of ischemia-reperfusion renal injury. Thus, CBLI expects 
that this class of drugs will be useful in limiting the tissue damage associated
with a number of different acute organ failure scenarios. Pre-clinical studies 
aimed at validating this hypothesis are ongoing. The anti-ischemia effect of 
CBLB502 also has a potentially important defense application. The compound is 
being tested for its ability to reduce tissue damage associated with the use of 
tourniquets to prevent excessive bleeding from wounded limbs. If effective in 
this scenario, CBLB502 could allow significantly broader use of tourniquets, 
which has been limited by the high risk of limb loss due to prolonged tissue 
hypoxia. Systemic and local effects of tourniquet use are described in

 http://www.jbjs.org.uk/cgi/reprint/62-B/3/385.pdf.





 Content-Type: text/html;

[ AUTOMATICALLY SKIPPING HTML ENCODING! ] 

Rate This Message: http://www.cryonet.org/cgi-bin/rate.cgi?msg=31822